Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Ascendis Pharma A/S (ASND) has a Wall Street consensus price target of $286.50, based on estimates from 24 covering analysts. With the stock currently trading at $233.50, this represents a potential upside of +22.7%. The company has a market capitalization of $14.33B.
Analyst price targets range from a low of $250.00 to a high of $342.00, representing a 32% spread in expectations. The median target of $267.50 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ASND trades at a trailing P/E of -54.7x and forward P/E of 49.1x. Analysts expect EPS to grow +228.2% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ASND stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for ASND is $286.5, representing 22.7% upside from the current price of $233.5. With 24 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ASND has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $286.5 implies 22.7% upside from current levels.
At a forward P/E of 49.0938x, ASND trades at a premium valuation. The consensus price target of $286.5 (22.7% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $342 for ASND, while the most conservative target is $250. The consensus of $286.5 represents the median expectation. These targets typically reflect 12-month expectations.
ASND is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ASND stock forecast based on 24 Wall Street analysts shows a consensus price target of $286.5, with estimates ranging from $250 (bear case) to $342 (bull case). The median consensus rating is "Buy".
ASND trades at a forward P/E ratio of 49.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on ASND, with a "Buy" consensus rating and $286.5 price target (22.7% upside). 22 of 24 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ASND analyst price targets range from $250 to $342, a 32% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $286.5 consensus represents the middle ground.